Glaxosmithkline halts RSV trial after safety recommendation

A late-stage study of Glaxosmithkline’s respiratory syncytial virus vaccine in pregnant women has been put on pause, the company informs Reuters.
Photo: Dado Ruvic/REUTERS / X02714
Photo: Dado Ruvic/REUTERS / X02714
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

British firm Glaxosmithkline (GSK) has paused a clinical study of its vaccine candidate against respiratory syncytial virus (RSV) due to a safety recommendation from an independent committee, as reported by news company Reuters.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading